ANTICOAGULATION STRATEGY FOR MECHANICAL PROSTHETIC VALVES IN PREGNANCY

Prepared by **Dr. Sidhartha Mullapudi**, DrNB (Cardiology), MD (General Medicine)
Last reviewed: October 2026

I THE CLINICAL DILEMMA (MATERNAL THROMBOSIS VS. FETAL EMBRYOPATHY)

- **High-Risk Cardio-Obstetric Scenario (mWHO Class III):** Pregnancy in a woman with a mechanical prosthetic heart valve carries an **approximately 1.4 percent maternal mortality risk** and a **5 to 10 percent risk of mechanical valve thrombosis** due to pregnancy-induced hypercoagulability (elevated fibrinogen and factors VII, VIII, X, vWF; reduced free Protein S; and increased GFR).
- **The Core Trade-Off:**
  - **Vitamin K Antagonists (VKAs — Warfarin / Acenocoumarol):** Provide the **most effective maternal protection** against prosthetic valve thrombosis (thrombosis rate <2 to 3 percent), but freely **cross the placenta**, carrying a dose-dependent risk of **first-trimester Warfarin Embryopathy (Weeks 6 to 12)**, miscarriage, and **fetal intracranial hemorrhage**.
  - **Heparins (LMWH and UFH):** Do **not** cross the placenta and are completely **safe for the fetus**, but carry a **significantly higher risk of maternal prosthetic valve thrombosis (5 to 9 percent even when monitored; >15 to 25 percent if unmonitored)**.

II FIRST TRIMESTER PROTOCOL (WEEKS 6 TO 12 OF GESTATION)

- **Decision Criterion:** The guideline strategy (2018 ESC Pregnancy Guidelines & 2020 ACC/AHA VHD Guidelines) is stratified strictly by the **pre-pregnancy baseline Warfarin dose** required to maintain a therapeutic INR:
- **Low-Dose Warfarin Requirement (Warfarin <=5 mg/day [or Acenocoumarol <=2 mg/day]):** The risk of Warfarin embryopathy is low (**<1 to 3 percent**). **Continuation of Warfarin throughout the first trimester is recommended (Class IIa)** after shared decision-making, as it offers superior maternal protection against fatal valve thrombosis.
- **High-Dose Warfarin Requirement (Warfarin >5 mg/day [or Acenocoumarol >2 mg/day]):** The risk of fetal embryopathy (**8 to 10 percent or higher**) and fetal loss (>30 percent) is high. **Discontinuing Warfarin between Weeks 6 and 12 and switching to in-hospital twice-daily dose-adjusted LMWH (with strict Anti-Xa monitoring) or continuous IV UFH (aPTT >=2.0x control) should be considered (Class IIa)**.
- **Very High Thrombotic Risk Caveat (Old-Generation Mitral Prosthesis, Prior Valve Thrombosis, or Atrial Fibrillation):** In women with an older-generation tilting-disc or caged-ball valve in the **Mitral Position** where heparin carries an extreme risk of fatal maternal valve thrombosis, continuing Warfarin during Weeks 6 to 12 may still be considered even at doses >5 mg/day after thorough maternal counseling.

III SECOND AND THIRD TRIMESTER PROTOCOL (WEEKS 13 TO 35 OF GESTATION)

- **Universal Warfarin Re-Initiation / Continuation (Class I):** Regardless of which regimen was used during the first trimester, **Warfarin is recommended from Week 13 until Week 36** in all pregnant women with mechanical heart valves.
- **Physiological Rationale:** Fetal organogenesis of the nasal cartilage and bone epiphyses is complete by **Week 12**, reducing the risk of classical Warfarin embryopathy to near zero during the second and third trimesters while providing stable maternal anticoagulation during peak hypercoagulability.
- **Adjunctive Low-Dose Aspirin:** Routine addition of **Low-Dose Aspirin** to VKA is no longer recommended in the 2018 ESC Guidelines; it is reserved for another indication such as pre-eclampsia prophylaxis.

Gestational Window	Strategy A: Baseline Warfarin <=5 mg/day	Strategy B: Baseline Warfarin >5 mg/day	Mandatory Target & Safety Rule
Weeks 0 to 5 (Pre-organogenesis)	Continue **Warfarin**	Continue **Warfarin** until Week 6	Confirm pregnancy early; verify baseline INR target (Mitral: 2.5–3.5; Aortic: 2.0–3.0)
Weeks 6 to 12 (Organogenesis Window)	**Continue Warfarin <=5 mg/d (Class IIa)** (or monitored BD LMWH / IV UFH)	**Switch to BD LMWH or IV UFH (Class IIa)** during Weeks 6–12	If on LMWH: **Weekly 4-h Peak Anti-Xa (1.0–1.2 U/mL MVR; 0.8–1.2 U/mL AVR) + Trough >=0.6 U/mL**
Weeks 13 to 35 (2nd & 3rd Trimesters)	**Continue Warfarin (Class I)**	**Resume Warfarin (Class I)**	Check **INR weekly or every 2 weeks**
Week 36 to Delivery (Peripartum Window)	**Stop Warfarin at Wk 36; switch to IV UFH or monitored BD LMWH (Class I)**	**Stop Warfarin at Wk 36; switch to IV UFH or monitored BD LMWH (Class I)**	Transition to **IV UFH (aPTT >=2.0x)** >=36 h before planned delivery; **stop IV UFH 4–6 h before delivery**

IV PERIPARTUM AND DELIVERY PROTOCOL (WEEK 36 TO POSTPARTUM)

- **Mandatory Switch at Week 36 (Class I):** Warfarin must be stopped at **36 weeks of gestation** (10 to 14 days prior to expected delivery) to allow the immature fetal liver to clear transplacental Warfarin and synthesize vitamin K-dependent clotting factors, preventing **fatal fetal intracranial hemorrhage** during vaginal descent.
- **Hospitalization and Peripartum Bridging (Class I):** The patient is admitted at Week 36 and transitioned to therapeutic **twice-daily LMWH** or **continuous IV UFH**, switching all patients to **continuous IV UFH (aPTT >=2.0x control) at least 36 hours prior to planned induction or cesarean delivery**.
- **Intrapartum and Postpartum Timing:**
  - **Stop IV UFH 4 to 6 hours prior to planned delivery** (or neuraxial catheter placement) and confirm a normal aPTT.
  - **Restart IV UFH 4 to 6 hours after delivery** once surgical hemostasis is assured and no obstetric bleeding is present, and re-initiate **Warfarin** 24 to 48 hours postpartum (safe during lactation).
  - **If Urgent Labor Occurs While on Warfarin (Class I):** Perform an **emergency Cesarean Section** (to protect the anticoagulated fetus from vaginal birth trauma) after maternal reversal with prothrombin complex concentrate/FFP and low-dose vitamin K.

V STRICT LABORATORY MONITORING TARGETS

- **LMWH Monitoring (Class I — Fixed Weight-Based Dosing Without Anti-Xa is Contraindicated [Class III]):**
  - **Peak Anti-Xa Level (drawn 4 hours after morning subcutaneous dose):** Target **1.0 to 1.2 IU/mL** for **mitral and right-sided mechanical valves**, and **0.8 to 1.2 IU/mL** for **aortic mechanical valves**, checked **weekly**.
  - **Trough Anti-Xa Level (drawn immediately prior to next dose):** Target **>=0.6 IU/mL** (per ESC 2018) to prevent sub-therapeutic gaps caused by rapid pregnancy renal clearance.
  - **IV UFH Monitoring:** Target **aPTT >=2.0 times control** (or anti-Xa 0.35 to 0.70 IU/mL).
  - **VKA Monitoring:** Check **INR weekly or every 2 weeks**, maintaining target INR (**2.5 to 3.5** for mechanical mitral valves or tilting-disc prostheses; **2.0 to 3.0** for bileaflet aortic valves without risk factors).

VI PRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

- **Dominance of Rheumatic Mechanical Mitral Valves:** In India, the vast majority of pregnant women with prosthetic valves have a **mechanical valve in the Mitral Position** (often bileaflet or tilting-disc **TTK Chitra** valves) implanted for juvenile **Rheumatic Heart Disease**, which carries a substantially higher thrombotic risk than an aortic prosthesis.
- **The "Unmonitored LMWH Trap" in Resource-Limited Settings:** Reliable, rapid-turnaround **chromogenic Anti-Xa assays** are frequently unavailable or unaffordable in Tier-2, Tier-3, and rural Indian centers, and empirical weight-based LMWH without weekly Anti-Xa dose escalation is a major cause of **acute obstructive prosthetic mitral valve thrombosis and maternal death** in Indian obstetric ICUs.
- **Pragmatic Indian Consensus Strategy:** When strict weekly Peak and Trough Anti-Xa monitoring cannot be guaranteed, many Indian cardio-obstetric centres favour **continuing Warfarin (or Acenocoumarol) throughout the first trimester** (especially when Warfarin dose is <=5 mg/day, and even at higher doses when reliable heparin monitoring is impossible) after documented multidisciplinary counseling of the patient and family, transitioning to monitored inpatient **IV UFH at 36 weeks** in a tertiary referral center.

KEY REFERENCES

- **Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.:** 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy, *European Heart Journal*, 2018.
- **Otto CM, Nishimura RA, Bonow RO, et al.:** 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease, *Circulation*, 2021.
- **van Hagen IM, Roos-Hesselink JW, Ruys TPE, et al. (ROPAC Investigators):** Pregnancy in Women With a Mechanical Heart Valve: Data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC), *Circulation*, 2015.